View ValuationProlight Diagnostics 将来の成長Future 基準チェック /06現在、 Prolight Diagnosticsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Medical Equipment 収益成長21.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • Jun 01First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: kr10.3m (up 132% from 1Q 2025). Net loss: kr10.4m (loss narrowed 5.0% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Chairman of the board Fredrik Alpsten was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Apr 22Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...分析記事 • Dec 23Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...お知らせ • May 23Prolight Diagnostics AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100.298496 million.Prolight Diagnostics AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100.298496 million. Security Name: Shares Security Type: Common Stock Securities Offered: 501,492,480 Price\Range: SEK 0.2 Transaction Features: Rights OfferingRecent Insider Transactions Derivative • Oct 23CEO & Director exercised options to buy kr450k worth of stock.On the 18th of October, Ulf Bladin exercised options to buy 3m shares at a strike price of around kr0.12, costing a total of kr300k. This transaction amounted to 345% of their direct individual holding at the time of the trade. Since December 2023, Ulf has owned 724.64k shares directly. Company insiders have collectively bought kr358k more than they sold, via options and on-market transactions, in the last 12 months.New Risk • Oct 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr97.4m (US$9.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr38m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 75% per year over the past 5 years. Shareholders have been substantially diluted in the past year (112% increase in shares outstanding). Market cap is less than US$10m (kr97.4m market cap, or US$9.48m). Minor Risk Revenue is less than US$5m (kr25m revenue, or US$2.4m).Reported Earnings • Aug 30Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: kr4.16m (up 32% from 2Q 2023). Net loss: kr11.2m (loss widened 40% from 2Q 2023).お知らせ • Jun 25Prolight Diagnostics and TTP Provides Update on MicroFlex DevelopmentProlight Diagnostics and TTP have developed the Point-of-Care system MicroFlex which brings the benefits of central-lab quality ELISA testing to more distributed environments with a compact and more user-friendly package.Reported Earnings • May 22First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr3.40m (down 2.7% from 1Q 2023). Net loss: kr8.93m (loss widened 18% from 1Q 2023).お知らせ • Apr 19Prolight Diagnostics AB (publ) to Report Fiscal Year 2023 Results on Apr 23, 2024Prolight Diagnostics AB (publ) announced that they will report fiscal year 2023 results on Apr 23, 2024お知らせ • Apr 10Prolight Diagnostics AB (publ), Annual General Meeting, May 14, 2024Prolight Diagnostics AB (publ), Annual General Meeting, May 14, 2024, at 13:00 Central European Standard Time. Location: Company’s office, Gasverksgatan 3 A, 222 29 Lund Sweden Agenda: To Establishment and approval of the voting list; to discuss Approval of the agenda; to discuss Election of one or two persons to verify the minutes; to Determination as to whether the Meeting has been duly convened; to Presentation of the annual report and the auditor’s report as well as the group accounts and the auditor’s report for the group for the financial year 2023; and to discuss other matters.New Risk • Mar 04New major risk - Revenue and earnings growthEarnings have declined by 44% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Earnings have declined by 44% per year over the past 5 years. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Market cap is less than US$10m (kr100.0m market cap, or US$9.69m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (kr19m revenue, or US$1.8m).New Risk • Feb 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 76% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (76% increase in shares outstanding). Market cap is less than US$10m (kr100.9m market cap, or US$9.62m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (kr15m revenue, or US$1.5m).New Risk • Dec 13New major risk - Revenue and earnings growthEarnings have declined by 36% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr49m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 36% per year over the past 5 years. Market cap is less than US$10m (kr90.6m market cap, or US$8.67m). Minor Risk Revenue is less than US$5m (kr36m revenue, or US$3.5m).New Risk • Oct 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr83.8m (US$7.53m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Market cap is less than US$10m (kr83.8m market cap, or US$7.53m). Minor Risk Revenue is less than US$5m (kr11m revenue, or US$1.0m).分析記事 • Jul 14Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • Jun 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (kr5.7m revenue, or US$538k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (kr120.8m market cap, or US$11.3m).Recent Insider Transactions • Jan 22Board Member recently bought kr172k worth of stockOn the 18th of January, Tobias Volker bought around 500k shares on-market at roughly kr0.34 per share. This transaction amounted to 82% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr184k more in shares than they have sold in the last 12 months.Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. No independent directors (6 non-independent directors). Director Maria Holmlund is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Chairman of the Board Ingemar Kihlstrom was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Nov 07Companies Like Prolight Diagnostics (NGM:PRLD) Can Afford To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...分析記事 • Jul 06We Think Prolight Diagnostics (NGM:PRLD) Can Easily Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...分析記事 • Mar 09Companies Like Prolight Diagnostics (NGM:PRLD) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Is New 90 Day High Low • Feb 23New 90-day low: kr1.59The company is down 18% from its price of kr1.93 on 25 November 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 16% over the same period.分析記事 • Nov 24Prolight Diagnostics (NGM:PRLD) Is In A Good Position To Deliver On Growth PlansEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is New 90 Day High Low • Nov 18New 90-day low: kr1.81The company is down 51% from its price of kr3.74 on 20 August 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 1.0% over the same period.Is New 90 Day High Low • Oct 21New 90-day low: kr2.24The company is down 14% from its price of kr2.61 on 23 July 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Prolight Diagnostics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NGM:PRLD - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202648-49-68-40N/A12/31/202542-50-57-37N/A9/30/202533-36-49-33N/A6/30/202532-30-47-33N/A3/31/202537-29-50-28N/A12/31/202436-27-50-28N/A9/30/202425-139-42-23N/A6/30/202425-140-38-19N/A3/31/202424-137-42-28N/A12/31/202324-135-40-25N/A9/30/202331-22-48-18N/A6/30/202333-17-46-16N/A3/31/202336-16-48-18N/A12/31/202235-12-36-9N/A9/30/202215-17-26-16N/A6/30/20229-14-17-11N/A3/31/20223-9-4-3N/A12/31/20210-7-7-7N/A9/30/20210-7-14-14N/A6/30/20211-6-10-7N/A3/31/20211-4-16-7N/A12/31/20201-4-21-7N/A9/30/20201-4-211N/A6/30/20200-3-29-4N/A3/31/20200-5-29-6N/A12/31/20190-4N/A-4N/A9/30/20190-5N/A-6N/A6/30/20190-6N/A-7N/A3/31/20190-6N/A-2N/A12/31/20180-6N/A-3N/A9/30/20181-5N/A-2N/A6/30/20180-4N/A0N/A3/31/20180-3N/A-5N/A12/31/20170-3N/A-5N/A9/30/2017N/A-4N/AN/AN/A6/30/2017N/A-3N/AN/AN/A3/31/2017N/A-3N/AN/AN/A12/31/2016N/A-2N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PRLDの予測収益成長が 貯蓄率 ( 2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: PRLDの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: PRLDの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: PRLDの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: PRLDの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PRLDの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/17 12:54終値2026/06/17 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Prolight Diagnostics AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Jun 01First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: kr10.3m (up 132% from 1Q 2025). Net loss: kr10.4m (loss narrowed 5.0% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Chairman of the board Fredrik Alpsten was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Apr 22Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
分析記事 • Dec 23Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
お知らせ • May 23Prolight Diagnostics AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100.298496 million.Prolight Diagnostics AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100.298496 million. Security Name: Shares Security Type: Common Stock Securities Offered: 501,492,480 Price\Range: SEK 0.2 Transaction Features: Rights Offering
Recent Insider Transactions Derivative • Oct 23CEO & Director exercised options to buy kr450k worth of stock.On the 18th of October, Ulf Bladin exercised options to buy 3m shares at a strike price of around kr0.12, costing a total of kr300k. This transaction amounted to 345% of their direct individual holding at the time of the trade. Since December 2023, Ulf has owned 724.64k shares directly. Company insiders have collectively bought kr358k more than they sold, via options and on-market transactions, in the last 12 months.
New Risk • Oct 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr97.4m (US$9.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr38m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 75% per year over the past 5 years. Shareholders have been substantially diluted in the past year (112% increase in shares outstanding). Market cap is less than US$10m (kr97.4m market cap, or US$9.48m). Minor Risk Revenue is less than US$5m (kr25m revenue, or US$2.4m).
Reported Earnings • Aug 30Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: kr4.16m (up 32% from 2Q 2023). Net loss: kr11.2m (loss widened 40% from 2Q 2023).
お知らせ • Jun 25Prolight Diagnostics and TTP Provides Update on MicroFlex DevelopmentProlight Diagnostics and TTP have developed the Point-of-Care system MicroFlex which brings the benefits of central-lab quality ELISA testing to more distributed environments with a compact and more user-friendly package.
Reported Earnings • May 22First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr3.40m (down 2.7% from 1Q 2023). Net loss: kr8.93m (loss widened 18% from 1Q 2023).
お知らせ • Apr 19Prolight Diagnostics AB (publ) to Report Fiscal Year 2023 Results on Apr 23, 2024Prolight Diagnostics AB (publ) announced that they will report fiscal year 2023 results on Apr 23, 2024
お知らせ • Apr 10Prolight Diagnostics AB (publ), Annual General Meeting, May 14, 2024Prolight Diagnostics AB (publ), Annual General Meeting, May 14, 2024, at 13:00 Central European Standard Time. Location: Company’s office, Gasverksgatan 3 A, 222 29 Lund Sweden Agenda: To Establishment and approval of the voting list; to discuss Approval of the agenda; to discuss Election of one or two persons to verify the minutes; to Determination as to whether the Meeting has been duly convened; to Presentation of the annual report and the auditor’s report as well as the group accounts and the auditor’s report for the group for the financial year 2023; and to discuss other matters.
New Risk • Mar 04New major risk - Revenue and earnings growthEarnings have declined by 44% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Earnings have declined by 44% per year over the past 5 years. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Market cap is less than US$10m (kr100.0m market cap, or US$9.69m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (kr19m revenue, or US$1.8m).
New Risk • Feb 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 76% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (76% increase in shares outstanding). Market cap is less than US$10m (kr100.9m market cap, or US$9.62m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (kr15m revenue, or US$1.5m).
New Risk • Dec 13New major risk - Revenue and earnings growthEarnings have declined by 36% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr49m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 36% per year over the past 5 years. Market cap is less than US$10m (kr90.6m market cap, or US$8.67m). Minor Risk Revenue is less than US$5m (kr36m revenue, or US$3.5m).
New Risk • Oct 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr83.8m (US$7.53m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Market cap is less than US$10m (kr83.8m market cap, or US$7.53m). Minor Risk Revenue is less than US$5m (kr11m revenue, or US$1.0m).
分析記事 • Jul 14Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • Jun 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (kr5.7m revenue, or US$538k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (kr120.8m market cap, or US$11.3m).
Recent Insider Transactions • Jan 22Board Member recently bought kr172k worth of stockOn the 18th of January, Tobias Volker bought around 500k shares on-market at roughly kr0.34 per share. This transaction amounted to 82% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr184k more in shares than they have sold in the last 12 months.
Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. No independent directors (6 non-independent directors). Director Maria Holmlund is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Chairman of the Board Ingemar Kihlstrom was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Nov 07Companies Like Prolight Diagnostics (NGM:PRLD) Can Afford To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Jul 06We Think Prolight Diagnostics (NGM:PRLD) Can Easily Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
分析記事 • Mar 09Companies Like Prolight Diagnostics (NGM:PRLD) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Is New 90 Day High Low • Feb 23New 90-day low: kr1.59The company is down 18% from its price of kr1.93 on 25 November 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 16% over the same period.
分析記事 • Nov 24Prolight Diagnostics (NGM:PRLD) Is In A Good Position To Deliver On Growth PlansEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Is New 90 Day High Low • Nov 18New 90-day low: kr1.81The company is down 51% from its price of kr3.74 on 20 August 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 1.0% over the same period.
Is New 90 Day High Low • Oct 21New 90-day low: kr2.24The company is down 14% from its price of kr2.61 on 23 July 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period.